Design, synthesis, antifungal activity, and ADME prediction of functional analogues of terbinafine

From the earlier quantitative structure–activity relationship (QSAR) and molecular modeling studies, a series of quinoline derivatives 5a–h mimicking terbinafine and containing different bulky aromatic rings in the side chain were designed using LeapFrog, a de novo drug design program. The designed compounds were synthesized and screened for antifungal activity in vitro against C. albicans. Of the ten compounds designed and synthesized, compounds 5c, d, f, h, and i exhibited minimum inhibitory concentration (MIC) in the range 4–25 μg/ml and were further evaluated for oral toxicity in animal model. The pharmacokinetic properties for these compounds were estimated in silico and compared with terbinafine. Compound 5h, N-methyl-N-[(2-naphthyl)methyl]-8-quinolinemethanamine, was found to be least toxic, possessing pharmacokinetic parameters close to those of terbinafine.

[1]  K. Subramanian truPK – human pharmacokinetic models for quantitative ADME prediction , 2005, Expert opinion on drug metabolism & toxicology.

[2]  P. Nussbaumer,et al.  Synthesis and structure-activity relationships of naphthalene-substituted derivatives of the allylamine antimycotic terbinafine. , 1993, Journal of medicinal chemistry.

[3]  P. Trown,et al.  Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice , 1985, Antimicrobial Agents and Chemotherapy.

[4]  P. Nussbaumer,et al.  Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment. , 1993, Journal of medicinal chemistry.

[5]  F. Odds Resistance of yeasts to azole-derivative antifungals. , 1993, The Journal of antimicrobial chemotherapy.

[6]  N. Ryder Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent , 1985, Antimicrobial Agents and Chemotherapy.

[7]  R. Diamond,et al.  The growing problem of mycoses in patients infected with the human immunodeficiency virus. , 1991, Reviews of infectious diseases.

[8]  Panos Macheras,et al.  In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.

[9]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[10]  C. Hitchcock Cytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals. , 1991, Biochemical Society transactions.

[11]  D. Denning,et al.  Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. , 1991, The Journal of antimicrobial chemotherapy.

[12]  M. Richardson Opportunistic and pathogenic fungi. , 1991, The Journal of antimicrobial chemotherapy.

[13]  N S Ryder,et al.  Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. , 1984, Science.

[14]  P. Nussbaumer,et al.  Synthesis and structure-activity relationships of benzo[b]thienylallylamine antimycotics. , 1991, Journal of medicinal chemistry.

[15]  G. Daum,et al.  Squalene and ergosterol biosynthesis in fungi treated with naftifine, a new antimycotic agent , 1982 .

[16]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[17]  J. Adler,et al.  The functional importance of structural features of ergosterol in yeast. , 1978, The Journal of biological chemistry.

[18]  M. Akova,et al.  Emergence ofCandida krusei infections after therapy of oropharyngeal candidiasis with fluconazole , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[19]  P. Nussbaumer,et al.  Synthesis and structure-activity relationships of the novel homopropargylamine antimycotics. , 1994, Journal of medicinal chemistry.

[20]  M. Nettleman,et al.  Secular Trends in the Epidemiology of Nosocomial Fungal Infections at a Teaching Hospital in Taiwan, 1981 to 1993 , 1997, Infection Control & Hospital Epidemiology.

[21]  Johnson,et al.  Predicting human safety: screening and computational approaches. , 2000, Drug discovery today.

[22]  P. Hawkey,et al.  Medical bacteriology : a practical approach , 1989 .

[23]  C. Beck-Sague,et al.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. , 1993, The Journal of infectious diseases.

[24]  P. Nussbaumer,et al.  Synthesis and structure-activity relationships of side-chain-substituted analogs of the allylamine antimycotic terbinafine lacking the central amino function. , 1995, Journal of medicinal chemistry.

[25]  C. Sonnenschein,et al.  Failure of fluconazole therapy inCandida krusei fungemia , 1991, European Journal of Clinical Microbiology and Infectious Diseases.

[26]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[27]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[28]  V. Kulkarni,et al.  Comparative molecular field analysis of fungal squalene epoxidase inhibitors. , 1999, Journal of medicinal chemistry.